Fernandez-Garza Luis E, Dominguez-Vigil Irma G, Garza-Martinez Jose, Valdez-Aparicio Erick A, Barrera-Barrera Silvia A, Barrera-Saldana Hugo A
Innbiogem SC/Vitagenesis SA at National Laboratory for Services of Research, Development, and Innovation for the Pharma and Biotech Industries (LANSEIDI) of CONACyT Vitaxentrum Group, Monterrey, Nuevo Leon, Mexico.
Laboratory for Translational Research, Rudy L. Ruggles Biomedical Research Institute, Nuvance Health, Danbury, CT, USA.
World J Oncol. 2021 Aug;12(4):85-92. doi: 10.14740/wjon1383. Epub 2021 Jul 10.
Ovarian cancer (OC) represents a serious health problem worldwide. In Mexico, most OC patients are detected at late stages, consequently making OC one of the leading causes of death in women after reaching puberty. Personalized medicine (PM) provides an individualized therapeutic opportunity for treating each patient relying on "omic" tools to match the correct drug with the specific pathogenic genomic signature. PM can help predict the best therapeutic option for each affected woman suffering from OC. In recent years, Mexico has made contributions to the PM of OC; however, it still has a long way to go for its full implementation in the country's health system.
卵巢癌（OC）是全球范围内一个严重的健康问题。在墨西哥，大多数OC患者在晚期才被发现，因此OC成为青春期后女性主要死因之一。精准医学（PM）借助“组学”工具为每位患者提供个性化治疗机会，以将正确药物与特定致病基因组特征相匹配。PM有助于为每位患OC的女性预测最佳治疗方案。近年来，墨西哥在OC的精准医学方面做出了贡献；然而，要在该国卫生系统中全面实施仍有很长的路要走。
